LIQUID BIOPSY Cell-free DNA analysis is being explored in


autoimmune disorders, infectious diseases, transplant rejection monitoring, and neurodegenerative conditions


(ctDNA) – and carries cancer-specific genetic alterations including point mutations, copy number variations, methylation changes, and structural rearrangements. While cfDNA has garnered significant


atention, liquid biopsy encompasses a broader range of circulating biomarkers: Circulating tumour cells (CTCs): Intact cancer cells that detach from primary or metastatic tumours and enter the bloodstream. Though rare (typically 1–10 CTCs per 10 million blood cells), they provide valuable information about tumour heterogeneity, metastatic potential, and can be cultured for functional studies.2 Extracellular vesicles (EVs): Membrane-bound particles released by cells, including exosomes (30–150 nm) and microvesicles (100–1000 nm). Cancer-derived EVs contain proteins, lipids, and nucleic acids that reflect the molecular characteristics of their cells of origin, offering insights into intercellular communication within the tumour microenvironment. Tumour-educated platelets (TEPs): Platelets that have interacted with tumour cells and subsequently altered their RNA profile. These changes can serve as biomarkers for cancer detection and classification, revealing how tumours influence distant cellular components.


Research applications for liquid biopsy


Tumour heterogeneity and evolution One of the most significant contributions of liquid biopsy to cancer research has been in elucidating tumour heterogeneity and clonal evolution. Traditional tissue biopsies provide only a snapshot of a single region of a tumour at one time point, potentially missing the complex spatial and temporal heterogeneity that characterises most cancers. Liquid biopsy offers a more


comprehensive view by sampling ctDNA released from multiple tumour regions simultaneously. Research using serial liquid biopsies has revealed how tumours evolve over time, particularly in response


to therapeutic pressures.3 For example,


studies in metastatic breast cancer have demonstrated the emergence of ESR1 mutations during aromatase inhibitor therapy, providing insights into resistance mechanisms that would be difficult to capture with conventional approaches. The ability to track subclonal populations non-invasively has transformed our understanding of cancer as a dynamic, evolving disease rather than a static entity.3


This perspective has


profound implications for therapeutic strategies, suggesting that adaptive approaches targeting emerging resistant clones may be necessary for durable responses.


Mechanisms of treatment resistance Liquid biopsy has become an invaluable tool for investigating mechanisms of treatment resistance in cancer. By analysing ctDNA before, during, and after therapy, researchers can identify genetic alterations associated with resistance, and track their emergence in real-time.2 In non-small cell lung cancer (NSCLC), liquid biopsy studies have revealed multiple resistance mechanisms to EGFR tyrosine kinase inhibitors, including the T790M mutation, MET amplification, and histological transformation.3


Similarly,


in colorectal cancer, the emergence of KRAS mutations has been observed during anti-EGFR therapy, providing a molecular explanation for acquired resistance. Beyond identifying known resistance


mechanisms, unbiased approaches like whole-exome sequencing of cfDNA have uncovered novel alterations associated with treatment failure. These discoveries have led to the development of next- generation therapies specifically designed to overcome resistance, exemplifying how liquid biopsy research directly informs therapeutic innovation.


Tumour microenvironment and immune interactions While initially focused on tumour-derived materials, liquid biopsy research has expanded to investigate the broader tumour ecosystem, including interactions with the immune system and stromal components. Cell-free DNA methylation


paterns can reflect the tissue of origin and cellular composition of tumours, providing insights into the tumour microenvironment.4 Recent studies have demonstrated


that cfDNA fragmentation paterns and nucleosome positioning can reveal chromatin accessibility states associated with different cell types within the tumour.4


This information helps


researchers understand how cancer cells interact with their surrounding environment and how these interactions influence treatment response. In immunotherapy research, liquid


biopsy has proven particularly valuable. Studies have shown correlations between ctDNA dynamics and response to immune checkpoint inhibitors, with early decreases in ctDNA levels predicting favourable outcomes.2


Furthermore,


analysis of T-cell receptor repertoires in circulation can provide insights into the diversity and clonality of anti-tumour immune responses, helping to elucidate mechanisms of immunotherapy success or failure.


Technological advances in cfDNA analysis for research


Extraction challenges and solutions


The analysis of cfDNA presents unique technical challenges that have driven significant methodological innovations in research setings. The extremely low concentration of cfDNA in circulation, typically 1–10 ng/mL in healthy individuals and slightly higher in cancer patients, necessitates highly efficient extraction methods.1


This challenge is particularly


pronounced in early-stage disease, where the tumour fraction (percentage of cfDNA that is tumour-derived) may be less than 0.1%. Additional complications include: Contamination risk: lysis of white blood cells during sample processing can release genomic DNA, diluting the cfDNA signal Fragmentation: The highly fragmented nature of cfDNA requires specialised extraction methods to capture short fragments efficiently Pre-analytical variables: Collection tubes, processing time, storage conditions, and centrifugation protocols all impact cfDNA yield and quality Automation requirements: High- throughput research demands reproducible results across large sample volumes.


Advanced magnetic bead-based extraction technologies have addressed many of these limitations. The chemagic cfDNA


February 2026 WWW.PATHOLOGYINPRACTICE.COM 27


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56